Preferred Label : Atezolizumab and Recombinant Human Hyaluronidase;
NCIt synonyms : Atezolizumab with rHuPH20; Atezolizumab rHuPH20; Atezolizumab-rHuPH20; Recombinant Human Hyaluronidase Mixed with Atezolizumab; Atezolizumab/rHuPH20 Co-formulation; Atezolizumab and Hyaluronidase; Tecentriq/rHuPH20; Atezolizumab and Recombinant Human Hyaluronidase-tqjs; Atezolizumab and Hyaluronidase-tqjs; atezolizumab/Hyaluronidase-tqjs;
NCIt definition : A co-formulation composed of atezolizumab, a humanized, Fc optimized, monoclonal antibody
directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274),
and a recombinant form of human hyaluronidase, with potential immune checkpoint inhibitory
and antineoplastic activities. Upon subcutaneous administration of atezolizumab and
hyaluronidase, atezolizumab targets and binds to PD-L1, blocking its binding to and
activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated
T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse
T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents
binding of this ligand to B7.1 (CD80) expressed on activated T-cells, which further
enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human
cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to
PD-1 on T-cells suppresses the immune system and results in increased immune evasion.
PD-1, a transmembrane protein, is a negative regulator of the immune system that limits
the expansion and survival of CD8 T-cells. The Fc region of atezolizumab is modified
in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC)
or complement-dependent cytotoxicity (CDC). Hyaluronidase hydrolyzes and degrades
the glycosaminoglycan hyaluronic acid (HA), thereby decreasing interstitial viscosity
and enhancing penetration of atezolizumab through the interstitial space. This facilitates
the delivery of atezolizumab to PD-L1-expressing tumor cells.;
Drug name : Tecentriq Hybreza;
NCI Metathesaurus CUI : CL1778814;
Origin ID : C186549;
UMLS CUI : C5670627;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
